Samsung Bioepis Achieves 1.5 Trillion KRW in Overseas Biosimilar Sales... Record High

[Asia Economy Reporter Lee Chun-hee] Samsung Bioepis's five biosimilars (biopharmaceutical generics) achieved a record high overseas sales of approximately 1.5 trillion KRW last year.

Samsung Bioepis announced on the 18th that the overseas sales of its five biosimilars sold through overseas marketing partners reached $1.2551 billion (about 1.5025 trillion KRW) last year. This represents an 11% sales growth compared to the previous year's sales of $1.1258 billion. As of the fourth quarter of last year, sales amounted to $338.9 million (about 406 billion KRW), a 13% increase compared to the same period last year.

Samsung Bioepis sells biosimilar products including three autoimmune disease treatments (▲Renflexis (European launch name Flixabi) ▲Brensys (Benepali) ▲Hadlima (Imraldi)) and two anticancer agents (▲Ontruzant ▲Avsola) in cooperation with marketing partners such as Organon and Biogen.

Accordingly, Samsung Bioepis has continuously disclosed the combined sales performance of its overseas partners. Biogen and Organon announced their fourth quarter and annual results for last year on the 3rd and 17th (local time), respectively. However, these sales do not directly translate into Samsung Bioepis’s revenue. Under partnership agreements, the amounts received are calculated at a certain ratio and recorded as Samsung Bioepis’s actual sales.

By company, Biogen, which supplies the three autoimmune disease treatments to Europe, achieved sales of $831.1 million, leading a 4% growth compared to the previous year. Organon, which sells all five biosimilars, recorded sales of $424 million, marking a 28% sales growth. Organon particularly attributed this performance to the increase in Renflexis sales in the United States.

A Samsung Bioepis official said, “Based on last year’s achievements, we plan to work closely with our partners to expand product sales this year as well. We will further strengthen our position as a global leader in the biosimilar industry by expanding our product portfolio into the ophthalmology field.”

Samsung Bioepis recently received sales approvals in Europe and the United States for 'Byooviz,' a biosimilar of Roche’s ophthalmic disease treatment 'Lucentis' for macular degeneration. The product is expected to be supplied worldwide, starting with sales in the United States by Biogen after June.

This content was produced with the assistance of AI translation services.